

## PERSONAL INFORMATION

## Valentina-Oana Buda



 Timisoara (Romania)



 [buda.valentina.oana@gmail.com](mailto:buda.valentina.oana@gmail.com); [buda.valentina@umft.ro](mailto:buda.valentina@umft.ro)

## WORK EXPERIENCE

01/05/2023 - present

**European Society of Clinical Pharmacy – Education Committee Member**

Coordination of educational activities within ESCP. Webinar program. Developing the scientific program/theme selection of ESCP events

20/09/2021 – present

**Associate Professor**

"Victor Babes" University of Medicine and Pharmacy, Timisoara (Romania)

Faculty of Pharmacy

Department of Clinical Pharmacy, Communication in pharmacy and Pharmaceutical care – Clinical pharmacy – course (2h) and laboratory (2h) – with the 5<sup>th</sup> year students of Faculty of Pharmacy (Romanian and French section), Pharmaceutical care – course (2h) – Romanian and French section and Communication in pharmacy - courses

02/05/2021 - present

**Clinical Pharmacist**

City Hospital of Ineu, Arad county

Involvement in the antibiotic stewardship, writing antibiotic protocols, monitoring the analgesic consumption within the hospital, appropriate prescribing of drugs and dose adjustment in different situations

14/02/2021- 19/09/2021

**Associate Professor**

"Victor Babes" University of Medicine and Pharmacy, Timisoara (Romania)

Faculty of Pharmacy

Department of Pharmacology and Clinical Pharmacy – Clinical pharmacy – course (3h) and laboratory (2h) – with the 5<sup>th</sup> year students of Faculty of Pharmacy, Pharmaceutical care – course (2h) – Romanian and French section

01/09/2020 - 13/02/2021

**Lecturer**

"Victor Babes" University of Medicine and Pharmacy, Timisoara (Romania)

Faculty of Pharmacy

Department of Pharmacology and Clinical Pharmacy – Clinical pharmacy – course (3h) and laboratory (2h) – with the 5<sup>th</sup> year students of Faculty of Pharmacy – Romanian and French section

01/10/2010–31/08/2020

**University assistant**

"Victor Babes" University of Medicine and Pharmacy, Timisoara (Romania)

Faculty of Pharmacy

Department of Pharmacology and Clinical Pharmacy - Pharmacology (3h/lab – 3<sup>rd</sup> and 4<sup>th</sup> year of study) and Clinical pharmacy laboratories (2h/lab – 5<sup>th</sup> year of study) in Romanian and French

- 01/01/2013–31/12/2015 **Clinical pharmacy resident**  
Clinical Emergency Hospital, Timisoara (Romania)
- 15/04/2012–01/07/2012 **University assistant**  
"Vasile Goldis" Western University, Faculty of Medicine and Pharmacy, Arad (Romania)  
Department of Pharmacology - Pharmacology laboratories (2-3h/lab) in English, French and Romanian
- 16/11/2010–01/03/2012 **Head pharmacist**  
SC Catena Hygeia SRL, Timisoara (Romania)
- Coordinating the activities with other department on all operation issues.
  - Orientating the medical and nursing team on all drugs related issues
  - Convening drug committee, minuting the discussions and implementing the recommendations
  - Managing rejected claims, conducting gross margin analysing and generating reports for management
  - Participating in clinic committee and staff meetings
  - Checking the validity each drug's being distributed and sold and verifying dates of manufacturing and expiration.
  - Assisting customers or patients on medications to buy, whether it's generic or branded.
  - Doing other basic tasks of pharmacist if needed.
  - Ensuring availability of all pharmaceutical needs in order to attend all the necessity of the patients.
- 01/07/2005–01/10/2010 **PC Operator**  
SC Gina Farm SRL, Ineu, Arad (Romania)

## EDUCATION AND TRAINING

---

- 06/12/2023 **Defense of the habilitation thesis**  
IOSUD/IOD "Victor Babeş" University of Medicine and Pharmacy in Timisoara. PhD coordinator in Medicine field.  
Thesis title: Optimization of pharmacotherapy and new pharmacological approaches in pathologies with an inflammatory component.  
Order Minister of Education: 3886/28.02.2024
- 01/01/2022 – 26/02/2022 **WHO Course: Antimicrobial Stewarship: A competency-based approach – online course**  
World Health Organization
- 01/05/2021 – 30/10/2021 **Harvard Medical School – online courses**  
Immunology – Novel therapies for chronic inflammation  
Pharmacology - Essentials
- 20/01/2020-31/01/2020 **Personalized Medicine Internship**  
Erasmus University Medical Center, Rotterdam, Netherlands  
Under the coordination of prof. dr. Peter J. Van der Speak, department of Medical Bioinformatics
- 01/03/2017–10/06/2017 **Clinical pharmacy Internship**  
Universite Catholique de Louvain, Bruxelles, Belgium

Under the coordination of prof. dr. Olivia Dalleur, Anne Spinewine, Paul Tulkens

**PhD student**

01/10/2011–27/10/2016

"Victor Babes" University of Medicine and Pharmacy, Timisoara (Romania)

PhD in Medicine, Cardiology - coordinator - prof. Mirela Cleopatra Tomescu

Title: The effects of Perindopril and Candesartan on the vascular endothelium in hipertensive patients, evaluated by the quantification of pentraxin-3, endoglin and thrombospondin-1

01/01/2013–31/12/2015

**Clinical Pharmacy residency programme**

"Victor Babes" University of Medicine and Pharmacy, Timisoara (Romania)

01/10/2012–20/07/2013

**Master Programe - The pharmacotherapy management of elder people**

"Victor Babes" University of Medicine and Pharmacy, Timisoara (Romania)

01/10/2010–01/07/2012

**Master Programe - Biomedical statistics**

Universitatea Bucuresti, Bucuresti (Romania)

01/10/2005–01/10/2010

**Pharmacist**

"Victor Babes" University of Medicine and Pharmacy - Faculty of Pharmacy, Timisoara (Romania)

01/09/2001–01/06/2005

**High school graduate**

"Mihai Viteazul" Industrial High School, Ineu (Romania)

**PERSONAL SKILLS**

**Mother tongue(s)**

Romanian

**Other language(s)**

|                                | UNDERSTANDING |         | SPEAKING           |                   | WRITING |
|--------------------------------|---------------|---------|--------------------|-------------------|---------|
|                                | Listening     | Reading | Spoken interaction | Spoken production |         |
| English                        | C1            | C1      | C1                 | C1                | C1      |
| FCE Cambridge Certificate 2010 |               |         |                    |                   |         |
| French                         | C1            | C1      | C1                 | C1                | C1      |
| DALF Certificate 2018          |               |         |                    |                   |         |
| Spanish                        | A2            | A2      | A2                 | A2                | A2      |

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user  
Common European Framework of Reference for Languages

**Communication skills**

Volunteer - humanitarian campaigns, election  
 Organization and participation in student congress - local, national, international  
 Teamwork, communication skills, perseverance, responsible, organized, sociable

**Organisational / managerial skills**

Chief Pharmacist - 2010 - 2012

**Project manager** Young reserchers - PII-C4-TC-2016/16441-09 – The role of Perindopril and Candesartan in hypertensive patients with endothelial dysfunction– period: 2016 – 2017. Financed by:

UMF Victor Babes, Timisoara. Period: 12 months. Founded amount: 5 000 euro

**Project manager** – 5DOC/1425/03.02.2020 – A comprehensive *in vitro* and *in vivo* evaluation of *Aronia melanocarpa* (Michx.) Elliot standardized bio juice on blood pressure levels and endothelial damage. A prospective study. Financed by: UMF Victor Babes, Timisoara. Period: 36 months. Founded amount: 25 000 euro

**Job-related skills** Driving licence - B category

**Member of the following projects:**

- 3POSTDOC / 1238 / 30.01.2020 - *Populi gemmae* - a double gain for the pharmaceutical field: therapeutic potential and bio-source for green synthesis of silver nanoparticles. Funded by: UMF Victor Babes, Timisoara. Financing period: 36 months. Funded amount: 30,000 euros. Project director: Corina Danciu

- PN-III-P1-1.1.-TE-2016-1165 - Hyphenated and complementary instrumental techniques for the analysis, control and recovery of bioactive compounds used in hormone therapies. Funded by: UEFISCDI. Financing period: 24 months. Funded amount: RON 450,000. Project director: Ionut Ledeti

**Reviewer** (scientific referent) for:

- > **60 articles in ISI journals** (with impact factor 1 - 9) and
- > 15 articles in journals indexed in Pubmed and in international databases.

Coordinator of 30 undergraduate papers (including the year 2022/2023) within UMFVBT.

**Award-winning scientific papers** at national level: **28** (UEFISCDI, PRESCI Awards 2017, 2019, 2020, 2021, 2022, 2023)

Special Prize - National Conference of Clinical Pharmacy, ed. I, Bucharest, June 17 - 18, 2016

**Digital competence**

| SELF-ASSESSMENT        |                  |                  |                  |                  |
|------------------------|------------------|------------------|------------------|------------------|
| Information processing | Communication    | Content creation | Safety           | Problem solving  |
| Proficient user        | Independent user | Independent user | Independent user | Independent user |

Digital competences - Self-assessment grid

Microsoft Office

Pharmec - pharmacy management program

**Other skills** List of scientific publications (non exhaustive):

1) Romanescu M, Oprean C, Lombrea A, Badescu B, Teodor A, Constantin GD, Andor M, Folescu R, Muntean D, Danciu C, Dalleur O, Batrina SL, Cretu O, **Buda VO**. Current State of Knowledge Regarding WHO High Priority Pathogens—Resistance Mechanisms and Proposed Solutions through Candidates Such as Essential Oils: A Systematic Review. *International Journal of Molecular Sciences*. 2023; 24(11):9727. <https://doi.org/10.3390/ijms24119727> **ISI**, impact factor **5.6/2022**

2) Lombrea A, Romanescu M, Jianu N, Andor M, Suciu M, Man DE, Danciu C, Dehelean CA, **Buda V**. Sex-Related Differences in the Pharmacological Response in SARS-CoV-2 Infection, Dyslipidemia, and Diabetes Mellitus: A Narrative Review. *Pharmaceuticals*. 2023; 16(6):853. <https://doi.org/10.3390/ph16060853> **ISI**, impact factor **4.6/2022**

3) Badescu B, **Buda V\***, Romanescu M, Lombrea A, Danciu C, Dalleur O, Dohou AM, Dumitrascu V, Cretu O, Licker M, Muntean D. Current State of Knowledge Regarding WHO Critical Priority Pathogens: Mechanisms of Resistance and Proposed Solutions through Candidates Such as Essential Oils. *Plants (Basel)*. 2022 Jul 6;11(14):1789. doi: 10.3390/plants11141789. **ISI, impact factor 4.50/2022**

- 4) Romanescu M, **Buda V\***, Lombrea A, Andor M, Ledeti I, Suci M, Danciu C, Dehelean CA, Dehelean L. Sex-Related Differences in Pharmacological Response to CNS Drugs: A Narrative Review. *Journal of Personalized Medicine*. 2022; 12(6):907. <https://doi.org/10.3390/jpm12060907> **ISI, impact factor 3.5/2022**
- 5) **Buda V**, Prelipcean A, Cozma D, Man DE, Negres S, Scurtu A, Suci M, Andor M, Danciu C, Crisan S, Dehelean CA, Petrescu L, Rachieru C. An Up-to-Date Article Regarding Particularities of Drug Treatment in Patients with Chronic Heart Failure. *J Clin Med*. 2022;11(7):2020. doi: 10.3390/jcm11072020. **ISI, impact factor 4.614/2021**
- 6) **Buda V**, Prelipcean A, Cristescu C, Roja A, Dalleur O, Andor M, Danciu C, Ledeti A, Dehelean CA, Cretu O. Prescription Habits Related to Chronic Pathologies of Elderly People in Primary Care in the Western Part of Romania: Current Practices, International Recommendations, and Future Perspectives Regarding the Overuse and Misuse of Medicines. *Int J Environ Res Public Health*. 2021 Jul 1;18(13):7043. doi: 10.3390/ijerph18137043. **ISI, impact factor 4.614/2021**
- 7) **Buda V**, Brezoiu AM, Berger D, Pavel IZ, Muntean D, Minda D, Dehelean CA, Soica C, Diaconeasa Z, Folescu R, Danciu C. Biological Evaluation of Black Chokeberry Extract Free and Embedded in Two Mesoporous Silica-Type Matrices. *Pharmaceutics*. 2020 Sep 1;12(9):838. doi: 10.3390/pharmaceutics12090838. **ISI, impact factor 6.321/2020**
- 8) **Buda V**, Prelipcean A, Andor M, et al. Potentially Inappropriate Prescriptions in Ambulatory Elderly Patients Living in Rural Areas of Romania Using STOPP/START (Version 2) Criteria. *Clin Interv Aging*. 2020; 15:407-417. doi:10.2147/CIA.S233270 **ISI, impact factor 4.458/2020**
- 9) **Buda V**, Baul B, Andor M, et al. Solid State Stability and Kinetics of Degradation for Candesartan-Pure Compound and Pharmaceutical Formulation. *Pharmaceutics*. 2020;12(2):86. doi:10.3390/pharmaceutics12020086 **ISI, impact factor 6.321/2020**
- 10) Radu G, Luca C, Petrescu L, Bordejevic DA, Tomescu MC, Andor M, Citu I, Mavrea A, **Buda V** et al. The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia. *Neuropsychiatr Dis Treat*. 2020;16:545-555. doi:10.2147/NDT.S240349. **ISI, impact factor 2.570/2020 (coresp author)**
- 11) **Buda V**, Andor M, Baibata DE, Cozlac R, Radu G, Coricovac D, Danciu C, Ledeti I, Cheveresan A, Nica C, Tuduce P, Tomescu MC. Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril. *Drug Design Development and Therapy*. 2019; 13:1915-1924. **ISI, Impact factor: 3.216/2019.**
- 12) Muntean D, Licker M, Alexa E, POpescu I, Jianu C, **Buda V\***, Dehelean CA, Ghiulai R, Horhat F, Horhat D, Danciu C. Evaluation of essential oil obtained from *Mentha x piperita* L. against multidrug-resistant strains. *Infection and Drug Resistance*. 2019; 12:2905-2914. **ISI, factor de impact 2.984/2019**
- 13) Suci M, Suci L, Vlaia L, Voicu M, **Buda V**, Dragan L, Andor M, Vlaia V, Cristescu C. Prevalence and the patterns of the use of non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol among the general population. *Revista Farmacia*. 2019; 67(2):337-345. **ISI, factor de impact 1.607/2019**
- 14) Andor M, Dehelean L, Romosan AM, **Buda V**, Radu G, Caruntu F, Bordejevic A, Manea MM, Papava I, Bredicean CA, Romosan RS, Tomescu M. A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication. *Neuropsychiatric Disease and Treatment*. 2019; 15:349-355. **ISI, factor de impact 2.157/2019**
- 15) **Buda V**, Andor M, Petrescu L, Cristescu C, Baibata DE, Voicu M, Munteanu M, Citu I, Munteanu C, Cretu O, Tomescu MC. Perindopril Induces TSP-1 Expression in Hypertensive Patients with Endothelial Dysfunction in Chronic Treatment. *Int J Mol Sci*. 2017; 18(2). doi: 10.3390/ijms18020348. **ISI, factor de impact 3.687/2017**
- 16) **Buda V**, Andor M, Ledeti A, Ledeti I, Vlase G, Vlase T, Cristescu C, Voicu M, Suci L, Tomescu MC. Comparative Solid-State Stability of Perindopril Active Substance vs. Pharmaceutical Formulation. *Int J Mol Sci*. 2017; 15:18(1). doi: 10.3390/ijms18010164. **ISI, factor de impact**

3.687/2017

17) **Buda V**, Andor M, Cristescu C, Voicu M, Cochera F, Tuduce P, Petrescu L, Tomescu MC. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension. *Ir J Med Sci.* 2017; 186(3):621-629. doi: 10.1007/s11845-017-1580-5. **ISI, factor de impact 1.045/2017**

ISI abstracts

**Buda V**, Prelipcean A, Dalleur O, Suciu M, Suciu L, Buda S, Romanescu M, Mailat D, Mateoc T, Dohou A, Cristescu C, Petrescu L, Cretu O, Andor M. Underuse of Medicines in Romanian Elderly Population based on START v.2, 2015 Criteria. *Metabolism: Clinical and Experimental.* 2023; 142:155505 doi: 10.1016/j.metabol.2023.155505 **ISI, impact factor 9.8/2022**

**Buda VO**, Bina AM, Minda D, Danciu C, Dehelean CA, Muntean DM, Sturza A. Assessment of dose-dependent vasculoprotective effects of aronia extracts in mice aorta. *Journal of Molecular and Cellular Cardiology.* 2022; 173:124-125 (S124,P291), **ISI, impact factor 5.763/2021**

**Buda VO**, Prelipcean A, Andor M, Cristescu C, Suciu M, Suciu L, Mabda MC, Voicu M, Danciu C, Ledeti I, Petrescu L. Excessive prescription of NSAIDs and theophylline in primary care setting of Romanian elderly population. *Atherosclerosis.* 2021; 331:E270 ISI, impact factor **6.847/2021**

**Buda VO**, Dalleur O, Prelipcean A, Man DE, Cretu O, Andor M, Danciu C, Ledeti I, Petrescu L. Missuse of drugs in Romanian elderly population. *Atherosclerosis.* 2021; 331:E269-270 ISI, impact factor **6.847/2021**

**Buda VO**, Andor M, Tomescu MC, Cristescu C, Cretu O, Voicu M, Suciu L, Mabda MC, Danciu C, Ledeti I, Petrescu L. Decreased sEng plasma levels in hypertensive patients under chronic treatment with candesartan cilexetil. *Atherosclerosis.* 2020; 315:e260, <https://doi.org/10.1016/j.atherosclerosis.2020.10.818>, ISI, impact factor **3.919/2019**

**Buda VO**, Dalleur O, Prelipcean A, Buda S, Andor M, Baibata DE, Dohou A, Petrescu L, Cristescu C. Statins and beta blockers – the most frequently encountered potential prescribing omissions in rural Romanian elderly population. *Atherosclerosis.* 2020; 315:e236-e237, <https://doi.org/10.1016/j.atherosclerosis.2020.10.745>, ISI, impact factor **3.919/2019**

**Buda V**, Andor M, Tomescu MC, Cristescu C, Voicu M, Citu I, Cochera F, Gheorghiu CM, Borcan LC, Glarou ZMA, Tuduce P, Pascu F, Mavrea A, Voicu A, Petrescu L. ACE inhibitors and ARBs decrease more powerful the PTX-3 plasma levels of hypertensive patients with endothelial dysfunction compared with other anti-hypertensive drugs, in a chronic treatment. *European Heart Journal*, Volume 38, Issue suppl\_1, 1 August 2017, ehx502.P2637, <https://doi.org/10.1093/eurheartj/ehx502.P2637> ABSTRACT publicat ISI, **factor de impact 23.425/2017**

**Buda V**, Andor M, Cristescu C, Proks CM, Suciu L, Petrescu L, Andrica FM, Tuduce P, Pop D, Muntean C, Daraban A, Borcan LC, Daneasa D, Tomescu MC. The influence of perindopril on endoglin plasma levels compared with other antihypertensive drugs, in a chronic treatment. *European Heart Journal*, Volume 38, Issue suppl\_1, 1 August 2017, ehx502.P2633, <https://doi.org/10.1093/eurheartj/ehx502.P2633> ABSTRACT publicat ISI, **factor de impact 23.425/2017**

**Buda V**, Andor M, Cristescu C, Voicu M, Suciu L, Suciu M, Proks CM, Muntean C, Munteanu M, Tuduce P, But AR, Udrescu L, Baibata DM, Pop D, Tomescu MC. TSP-1 plasma levels in hypertensive patients with endothelial dysfunction after one year of treatment with ace inhibitors. *Atherosclerosis.* 2017; 263:e139-e140, doi: <https://doi.org/10.1016/j.atherosclerosis.2017.06.445> ABSTRACT publicat ISI, **factor de impact 4.467/2017**

